TMO
Thermo Fisher Scientific Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow -1.4% ·
net new positions -9.1%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +3 | 260.72M | $131.51B | +5 | −1 |
| Q1 2026 | 190 | +2 | 255.88M | $126.62B | +7 | −6 |
| Q4 2025 | 187 | +3 | 274.75M | $159.19B | +4 | — |
| Q3 2025 | 29 | -1 | 154.46M | $74.90B | +1 | −3 |
| Q2 2025 | 28 | +3 | 123.95M | $50.25B | +3 | — |
| Q1 2025 | 22 | -2 | 60.64M | $30.17B | — | −2 |
| Q4 2024 | 24 | +2 | 61.50M | $31.99B | +2 | — |
| Q3 2024 | 21 | -2 | 44.46M | $27.48B | — | −2 |
| Q2 2024 | 23 | — | 44.78M | $24.75B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 16.54M | +0.6% | $8.24B | 0.3% | ▲ Add | 2 | SEC ↗ |
| 2 | Capital World Investors ✦ | 11.06M | +17.3% | $5.50B | 0.9% | ▲ Add | 4 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 9.30M | -14.8% | $4.63B | 0.6% | ▼ Trim | 4 | SEC ↗ ×2 |
| 4 | Geode Capital Management ✦ (passive) | 8.13M | +3.4% | $4.03B | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 6.19M | +2.2% | $3.08B | 0.4% | ▲ Add | 4 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 2.72M | +1.9% | $1.35B | 0.6% | ▲ Add | 4 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 2.32M | -7.5% | $1.15B | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.60M | +11.8% | $794.03M | 0.2% | ▲ Add | 4 | SEC ↗ ×7 |
| 9 | Arrowstreet Capital ✦ | 655.94K | +77.6% | $326.39M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 10 | Baillie Gifford ✦ | 509.38K | -5.5% | $253.47M | 0.2% | ▼ Trim | 4 | SEC ↗ ×4 |
| 11 | Two Sigma Investments ✦ | 331.26K | -26.7% | $164.84M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 235.37K | -56.7% | $117.12M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | Adage Capital Partners ✦ | 233.45K | -40.2% | $116.17M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 209.26K | -5.4% | $102.36M | 0.1% | ▼ Trim | 4 | SEC ↗ ×6 |
| 15 | Millennium Management ✦ | 188.47K | -45.0% | $93.79M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 155.24K | -14.4% | $77.25M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 120.57K | -64.5% | $60.00M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 18 | Markel Group ✦ | 45.00K | +9.5% | $22.39M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 38.80K | -0.8% | $19.31M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 38.34K | +30.6% | $19.08M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 21 | Dodge & Cox ✦ | 26.11K | -0.1% | $12.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | GAMCO Investors ✦ | 3.91K | -5.1% | $1.95M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Third Point | $182.08M | was 2.4% |
| Marshall Wace | $171.84M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 24.30K shares, $11,944 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.73K sh · $2.29M
Officer · 400 sh · $245,752
Officer, Director · 62 sh · $38,982
Officer, Director · 33 sh · $20,677
Officer, Director · 101 sh · $63,166
Officer, Director · 79 sh · $49,613
Officer, Director · 2.15K sh · $1.35M
Officer, Director · 1.79K sh · $1.12M
Officer, Director · 3.01K sh · $1.89M
Officer, Director · 2.73K sh · $1.71M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology